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Polyketides by Type I PKSs
William B. Porterfield,1 Nannalin Poenateetai,1 and Wenjun Zhang1,2,3,*
SUMMARY
Polyketides produced by modular polyketide synthases (PKSs) are important small molecules widely
used as drugs, pesticides, and biological probes. Tagging these polyketides with a clickable function-
ality enables the visualization, diversification, andmode of action study through bio-orthogonal chem-
istry. We report the de novo biosynthesis of alkyne-tagged polyketides by modular type I PKSs
through starter unit engineering. Specifically, we use JamABC, a terminal alkyne biosynthetic machin-
ery from the jamaicamide B biosynthetic pathway, in combination with representative modular PKSs.
We demonstrate that JamABCworks as a trans loading system for engineered type I PKSs to produce
alkyne-tagged polyketides. In addition, the production efficiency can be improved by enhancing the
interactions between the carrier protein (JamC) and PKSs using docking domains and site-directed
mutagenesis of JamC. This work thus provides engineering guidelines and strategies that are
applicable to additional modular type I PKSs to produce targeted alkyne-tagged metabolites for
chemical and biological applications.
INTRODUCTION
Natural products produced by modular polyketide synthases (PKSs) have demonstrated their use as
therapeutics, industrial products, pesticides, and biological probes following intense study over the past
decades (Hertweck, 2009; Klaus and Grininger, 2018). Some well-known examples of these polyketides
include the antibiotic erythromycin and the immunosuppressant rapamycin, both of which were initially
isolated from bacterial sources and have been approved for clinical use for decades (Cottens et al.,
2019; Hertweck, 2009; Jelic and Antolovic, 2016). The process for discovery, diversification, and mode of
action elucidation of polyketides remains challenging and time consuming, although it has been improved
in recent years due tomany technical advancements. One such technology is to tag polyketides with a click-
able functionality, which has been demonstrated to facilitate the study of polyketide biosynthesis, biology,
and pharmacology through bio-orthogonal chemistry (DeGuire et al., 2015; Harvey et al., 2012; Hughes
et al., 2014; Kalkreuter et al., 2019a, 2019b; Koryakina et al., 2017; Musiol-Kroll et al., 2017; Riva et al.,
2014; Seidel et al., 2019; Zhu and Zhang, 2015). In particular, polyketides can be tagged through semi-syn-
thesis (DeGuire et al., 2015; Seidel et al., 2019), total synthesis (Staub and Sieber, 2008), precursor-directed
biosynthesis (Harvey et al., 2012; Koryakina et al., 2017; Musiol-Kroll et al., 2017; Seidel et al., 2017; Yan
et al., 2013), or de novo biosynthesis (Zhu et al., 2015a; Zhu and Zhang, 2015). In this work we aim to further
develop the strategy of de novo biosynthesis, which offers the unique advantage of not feeding the
biorthogonal moiety itself, which could lead to increased background due to the diffusible non-specific
nature of feeding starter or extender units. Instead the taggable group is incorporated by enzymatically
synthesizing both the complex polyketide scaffolds and the unique clickable functionality allowing
in situ bio-orthogonal chemical transformations.
Modular PKSs, often referred to as type I PKSs, have modules with multiple catalytic domains that perform
separate enzymatic activities and act as an assembly line to select and incorporate building monomers into
polyketide scaffolds (Jenke-Kodama and Dittmann, 2009; Keatinge-Clay, 2012; Khosla et al., 2014; Ladner
andWilliams, 2016) (Figure 1). The monomers used for extension, typically malonyl- or methylmalonyl-CoA,
are recognized by acyltransferase (AT) domains, and the carbon-carbon bond is formed through decarbox-
ylative Claisen condensations catalyzed by the ketosynthase (KS) domains. The megasynthases themselves
have been investigated and have undergone extensive engineering efforts due to their modular structures
that have captured scientists’ imagination with the possibility of producing on-demand, designer mole-
cules (Awakawa et al., 2018; Barajas et al., 2017; Chemler et al., 2015; Harvey et al., 2012; Kalkreuter and
Williams, 2018; Klaus and Grininger, 2018; Koryakina et al., 2017; Moss et al., 2013; Ranganathan et al.,
1999; Sundermann et al., 2013; Tang et al., 2000; Wlodek et al., 2017; Yonemoto et al., 2012; Yuzawa
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et al., 2017). Many of these engineering strategies have included efforts geared toward the inclusion of
functional chemical handles for subsequent drug discovery or chemical biology studies, albeit often em-
ploying fed precursors containing the functionality of interest (Kalkreuter et al., 2019a; Koryakina et al.,
2017; Mohammadi-Ostad-Kalayeh et al., 2018).
The terminal alkyne is a canonical bio-orthogonal functional group as it is small, stable, and can be selec-
tively reacted via copper-catalyzed azide-alkyne cycloaddition, where an azide containing a fluorophore,
mass tag, or other chemical moiety is attached (Prescher and Bertozzi, 2005; Zhu and Zhang, 2015). The
bio-orthogonality of alkynes is due to its chemical stability in biological environments and its rarity in
biology where only a small number of terminal alkyne-bearing secondary metabolites have been discov-
ered and even fewer biosynthetic pathways have been elucidated (Edwards et al., 2004; Fritsche et al.,
2014; Haritos et al., 2012; Lee et al., 1998; Marchand et al., 2019; McPhail et al., 2007; Minto and Blacklock,
2008; Moss et al., 2019; Ross et al., 2014). We recently identified and characterized an acyl carrier protein
(ACP)-dependent, three-protein pathway to generate the terminal alkyne functionality in E. coli (Zhu et al.,
2015a, 2015b, 2016). For example, in the biosynthesis of the cyanobacterial jamaicamide B, JamA, an acyl-
ACP synthetase, activates and loads 5-hexanoic acid onto JamC, a dedicated ACP. The resulting 5-hexa-
noyl-JamC is modified by JamB, a membrane-bound desaturase/acetylenase, to yield 5-hexynoyl-JamC as
a starter unit for the downstream PKS/nonribosomal peptide synthetase assembly line (Figure 1A) (Edwards
et al., 2004; Zhu et al., 2015a). JamABC thus represents a portable tri-gene cassette that may be useful for in
situ generation and incorporation of terminal alkynes into various molecular scaffolds on demand. Toward
this end, we demonstrated that PKS starter unit engineering is a feasible strategy to install the fatty alkynyl
starter unit generated by JamABC onto polyketide scaffolds, such as those generated by promiscuous type
III PKSs, which recognize both the acyl group and the acyl carrier (JamC) (Zhu et al., 2015a, 2015b). However,
Figure 1. Overview of the JamABC Cassette and Type I PKSs in This Work
(A) JamABC works together to produce 5-hexynoyl-JamC as a starter unit for the downstream PKS/nonribosomal peptide synthetase assembly line in
jamaicamide B biosynthesis.
(B) Native LipPKS1 and DEBSM6 domain organization and associated polyketide products.
(C) Engineered LipPKS1* and DEBSM6* used as representative modular PKSs in the current study.
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to generalize this strategy to other polyketide scaffolds, in particular those synthesized by modular type I
PKSs, additional model systems and protein engineering methods need to be explored.
Here we employ two well-studied type I PKSs, LipPKS1 and DEBSM6, to explore engineering strategies to
make alkyne-tagged polyketides. LipPKS1 is the first module in lipomycin biosynthesis that natively utilizes
an isobutyl starter unit presented by a loading ACP (Figure 1B) (Bihlmaier et al., 2006). DEBSM6 is the last
PKS module from the erythromycin biosynthetic pathway (Figure 1B) (Rawlings, 2001). In addition, engi-
neered LipPKS1 and DEBSM6 have been obtained to utilize malonyl-CoA instead of methylmalonyl-CoA
as the extender unit with the promiscuous DEBS thioesterase to promote the acid product release as
demonstrated from both in vitro biochemical studies and in E. coli (Yuzawa et al., 2017). These two engi-
neered modules are thus simple and convenient systems for in-depth assessment of the interaction be-
tween representative module PKSs and JamABC for alkyne-tagged polyketide biosynthesis. Considering
the known critical role of the cognate ACP (JamC) in the alkyne biosynthetic machinery (Su et al., 2018;
Zhu et al., 2015a), the recognition of JamC by PKSs is expected to play a key role in alkyne-tagged polyke-
tide synthesis and therefore is the focus of the present study.
RESULTS AND DISCUSSION
Alkyne-Tagged Polyketide Synthesis In Vitro
To probe the possible recognition of the 5-hexynoyl-JamC by PKSs, in vitro assays were initially performed
using the engineered LipPKS1 and DEBSM6modules. The reported engineered LipPKS1 was further modi-
fied by removing the AT and ACP loading domains to create a truncated version to facilitate the alternative
starter unit incorporation. We hypothesized that these engineered PKSs (termed LipPKS1* and DEBSM6*,
Figure 1C) without the loading domains would result in JamC to act in trans to selectively load and extend
JamC-linked acyl chains. For in vitro assessment we purified JamA, holo-JamC, and LipPKS1*/DEBSM6*
from E. coli after overexpression (Figure S1), or an E. coli BAP1 strain that contains a chromosomal copy
of the phosphopantetheinyl transferase Sfp that was used to ensure the post-translational modification
of carrier proteins to the pantetheinylated forms (Pfeifer et al., 2001). Purified enzymes were incubated
with 5-hexynoic acid, ATP, malonyl-CoA, and NADPH for alkyne-tagged polyketide biosynthesis in vitro
(Figure 2A). JamB activity for alkyne biosynthesis was not assessed in vitro due to the difficulty of obtaining
active and purified membrane proteins and was assessed later in vivo. The expected product, 3-hydroxy-7-
octynoic acid (1), was successfully produced by both engineered PKSs as confirmed by comparing with the
synthetic chemical standard (Figures 2B, 2C, and S2–S4, Scheme S1). Interestingly, replacement of 5-hex-
ynoyl-JamC by 5-hexynoyl-CoA, which was generated in situ using a promiscuous acyl-CoA ligase Orf35
(Zhang et al., 2010), dropped the formation of 1 to trace amounts, demonstrating a preference of these
two PKSs toward JamC over CoA as the acyl carrier (Figures 2B, 2C, and S2).
Evaluation of Docking Domain Strategy to Improve JamC-PKS Interactions
As protein-protein interactions are known to dominate the turnover of chimeric PKS assembly lines (Klaus
et al., 2016), we proposed that improved communication between the upstream JamC and the downstream
KS could lead to a more efficient alkyne-tagged polyketide biosynthesis. Docking domains, often found on
the C terminus of ACPs (ddACP) and the N terminus of KSs (ddKS), have been shown to be important for pro-
tein-protein interactions in PKSs (Gokhale et al., 1999; Tsuji et al., 2001; Zeng et al., 2016). We then set out to
evaluate the strategy of fusing known docking domains to the C terminus of JamC and the N terminus of
the LipPKS1*/DEBSM6* KS domains to improve protein recognition. In particular, we chose to utilize the
class 2 docking domains from the cyanobacterial curacin pathway as the pair Cdd
CurK (ddACP) and
Ndd
CurL(ddKS) was shown to be modular and portable (Whicher et al., 2013). We also chose the related
docking domain pair Cdd
JamK (ddACP) and Ndd
JamL(ddKS) from the jamaicamide pathway as moving dock-
ing domains within pathways was shown to bemore successful than inter-pathway swapping (Klaus and Gri-
ninger, 2018; Klaus et al., 2016; Whicher et al., 2013). The fusion of these docking domains to JamC and
PKSs did not significantly impact the expression and folding of these proteins (Figures S1 and S5).
In vitro product formation assays using purified proteins demonstrated the success of this strategy in
generating product 1 (Figures 2 and S6). The adoption of the pair of Cdd
JamK and Ndd
JamL had minimal
effect on the production of 1, whereas the pair of Cdd
CurK and Ndd
CurL led to significantly more amount
of 1 in both PKS systems (3-fold for LipPKS1* and 40-fold for DEBSM6*) (Figures 2B and 2C). Control
experiments using only one of the docking domains produced less products than using the pair for Cdd
CurK
and Ndd
CurL. In addition, the poor production of 1 with the docking domain fused to JamC excluded the
possibility of improved recognition of modified JamC by JamA (Figures 2B and 2C), indicating that the
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improved communication between the engineered JamC and KS due to the docking domains is the main
contributor for higher production of 1 in vitro.
Evaluation of Site-Directed Mutagenesis of JamC to Improve JamC-PKS Interactions
In addition to docking domains, we also wanted to identify a less-intensive engineering strategy to improve
JamC-PKS communication. Mutating JamC without perturbation to the large megasynthase would make
this strategy more easily adaptable to different systems. From the well-studied DEBS system, it has
been shown that direct ACP-KS protein-protein interactions during translocation are selective, and key res-
idues within helix I of ACP have been identified that contribute to chain translocation specificity (Kapur
et al., 2012; Klaus et al., 2016). Inspired by the previous successful studies, we identified the corresponding
residue in JamC (E32) that may play an important role in ACP-KS interactions through sequence alignments
and structural modeling (Figure S7). To mimic the native upstream ACP, we chose the mutations E32T for
Figure 2. In Vitro Assessment of Alkyne-Tagged Polyketide Biosynthesis Using LipPKS1* and DEBSM6*
(A) Overview scheme of in vitro reactions between JamA/JamC and engineered PKSs to produce 3-hydroxy-7-octynoic
acid (1).
(B) Formation of 1 by LipPKS1* under various reaction conditions and engineering strategies.
(C) Formation of 1 by DEBSM6* under various reaction conditions and engineering strategies. Engineered PKS cartoon is
truncated for clarity. All graphs are shown as relative product formed compared with the JamC/PKS with no modifications
calculated from integration of the extracted ion chromatogram (EIC) for compound 1 (set as 1). Error bars indicate SEM for
n R 2 independent experiments.
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LipPKS1* and E32H for DEBSM6* based on alignments to the respective ACPs found upstream in the native
systems (Figure S7). These two JamC mutants were cloned, overexpressed, and purified from BAP1 with a
similar yield to the wild-type protein (Figure S1). In vitro product formation assays showed that the forma-
tion of 1 increased approximately 7-fold with LipPKS1* (Figure 2B) and 2-fold with DEBSM6* (Figure 2C).
These fold increases demonstrated the effectiveness of this strategy in improving the production of
alkyne-tagged polyketides in vitro, most likely due to an improved JamC communication with modular
PKSs.
Perturbation of JamB Activity by JamC Engineering
In vitro biochemical assays demonstrated the success of protein engineering in improving the recognition
of JamC by PKSs to promote the translocation of the alkynyl starter unit. However, the potential impact of
JamC modification on the activity of JamB, the desaturase/acetylenase that functions on a JamC-tethered
substrate to form a terminal alkyne, is unclear. As it is difficult to reconstitute and quantify the activity of the
membrane-bound JamB in vitro, we then tried to implement the biosynthetic machinery of alkyne-tagged
polyketides in E. coli to assess the possible impact. In addition, the titers of relevant products were also
quantified in E. coli to probe the effectiveness of two engineering strategies to improve JamC-PKS inter-
actions in vivo. Combinations of JamA, B, C, PKSs, and their variants were expressed in an E. coli BAP1
strain under a T7 promoter to obtain various engineered strains. A single mutation in JamB (M5T) identified
in previous work, presumably with an improved interaction with the electron donor, was used in all strains to
increase the alkyne titer in E. coli (Zhu et al., 2016). All strains were grown with 5-hexenoic acid feeding,
followed by extraction and quantification of 3-hydroxy-7-octenoic acid (2) and 3-hydroxy-7-octynoic acid
production (1), by fitting to a standard curve of synthesized standards generated through liquid chroma-
tography-high-resolution mass spectrometric analysis (Scheme S1, Figures S3, S4, S8, and S9). The product
2 was expected to be a side product due to the activities of JamA, C, and PKS without the action of JamB
(Figure 3A). Other possible products were also analyzed, as it is conceivable that the PKSs accept different
fatty acyl starter units in vivo via JamC or other acyl carriers (Figure S10).
An initial investigation of the titer of compound 1 produced by the co-expression of JamA, B, C, and
LipPKS1*/DEBSM6* demonstrated that DEBSM6* produced compound 1 (0.014 mg/L) significantly less
than LipPKS1* (0.071 mg/L). Much higher amounts of products other than 1 and 2 with a longer acyl chain
were generated by DEBSM6* in vivo (Figure S10), consistent with the native acyl chain length accepted by
LipPKS1*/DEBSM6* (C4 versus C13). We concluded that DEBSM6* would not be an effective in vivomodel
system to probe the activity of JamB due to complicated product profiles and thus limited the in vivo study
to LipPKS1*.
The products 1 and 2 were produced by LipPKS1* in an approximately 1:5 ratio, and this efficiency was set
to be a relative JamB activity of 100% (Figure 3B). This product ratio was dropped 4-fold when either
docking pair was used, suggesting that the fusion of a docking domain to JamC affected its recognition
by JamB (Figure 3B). In contrast, the E32T point mutation of JamC had minimal effect on the product ratio
while increasing the titer of 16-fold to 0.42 mg/L, consistent with previous observations that the helix I of
ACP did not play an important role in interacting with JamB (Su et al., 2018; Zhu et al., 2016). We next
probed the combined product titer of alkyne 1 and alkene 2 to assess the effectiveness of the two engineer-
ing strategies in their ability to improve JamC-LipPKS1* interactions in vivo (Figure 3C). Consistent with the
trends observed in vitro, the combined titer improved more than 10- and 20-fold using docking domains
Cdd
CurK/Ndd
CurL and Cdd
JamK/Ndd
JamL, respectively, and 10-fold using JamC (E32T), demonstrating
the success of either strategy in improving JamC-PKS interactions in vivo (Figure 3C).
Finally, we probed the possible synergistic effects of the two engineering strategies in improving the
alkyne-tagged polyketide biosynthesis in vivo. We observed additive effects when using docking domains
and the JamC point mutation in improving JamC- LipPKS1* interactions. The combined titer of 1 and 2
roughly equaled the sum of that when either engineering strategy was used. The maximum amount of
product obtained was 16 mg/L from JamC(E32T)-CddJamK/NddJamL-LipPKS1*, an approximately 39-fold
increase from unmodified JamC/LipPKS1* (Figure 3C). However, due to the expected disruption of
JamB activity when the docking domain is fused to JamC, the absolute titer of the alkyne product 1 was
not increased when using both engineering strategies compared with the JamC mutagenesis alone (Fig-
ure 3B). These results further highlight the importance of JamB efficiency in de novo alkyne synthesis, which
remains to be a limiting step in the production of alkyne-tagged polyketides.
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Limitations of the Study
Although the current results demonstrate a great potential of de novo biosynthesizing alkyne-tagged polyketi-
des by engineering both the alkyne biosynthetic machinery and modular type I PKSs, the strategy is limited to
incorporate an alkynyl starter unit, which needs to be tolerated by PKSs. It is expected toworkwell with PKSswith
a native starter unit resembling the alkyne-containing acyl group presented by the alkyne biosynthetic machin-
ery, such as in the case of LipPKS1, but may not work with PKSs recognizing very different starter units, such as in
the case of DEBSM6. This is particularly exemplified by the in vivo results of DEBSM6, in which a complex meta-
bolic background significantly decreased the efficiency of alkyne-tagged polyketide biosynthesis by these PKSs.
Figure 3. In Vivo Assessment of Alkyne-Tagged Polyketide Biosynthesis Using LipPKS1*
(A) Overview scheme of in vivo reactions between JamABC and LipPKS1* to produce 3-hydroxy-7-octynoic acid (1) and
3-hydroxy-7-octenoic acid (2).
(B) Quantification of alkyne product titers resulting from the engineered JamC and LipPKS1*. Alkyne 1 product titers are
shown in blue (left y axis), and the relative JamB activities are shown in green (right y axis).
(C) Quantification of total product titers resulting from the engineered JamC and LipPKS1*. LipPKS1* cartoon is truncated
for clarity. All titers shown have subtracted background from a control strain lacking JamC to better reflect the interaction
between JamC and LipPKS1*. All error bars represent SEM for n R 3 biological replicates.
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Conclusion
We have successfully demonstrated that carrier protein-dependent alkyne biosynthetic machinery can
work as a trans loading system for truncated Type I PKSs to produce alkyne-tagged polyketides both
in vitro and in vivo. Two protein engineering strategies were explored to improve the interaction between
the carrier protein within the alkyne biosynthetic machinery (JamC) and modular PKSs. This included the
employment of PKS docking domains and site-directed mutagenesis of JamC to increase acyl chain trans-
location specificity. Both strategies were shown to be successful, leading to enhanced recognition of JamC
by modular PKSs and thus improved alkyne-tagged polyketide production. In addition, the effects of both
engineering strategies to improve protein-protein interactions were additive, leading to an 39-fold in-
crease in the polyketide production by an engineered LipPKS1 in E. coli. It is also notable that the instal-
lation of a docking domain on JamC, but not the site-directed mutagenesis, disrupted its recognition by
JamB in alkyne-tagged polyketide production. Furthermore, the native acyl group specificity of modular
PKSs was suggested to be important for alkyne-tagged polyketide production, in particular in vivo where
competing acyl groups were present. In summary, this work has shown the first examples of de novo biosyn-
thesis of alkyne-tagged polyketides by modular type I PKSs through starter unit engineering and further
provided engineering guidelines and strategies that are expected to be applicable to other modular
PKSs to produce targeted alkyne-tagged metabolites for drug discovery and chemical biology studies.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100938.
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Supplementary Figures  
A 
 
B 
number plasmid protein 
yield 
(mg/L) 
Expected size 
(kDa) 
1 pWP08 JamC 5.0 14.3 
2 pWP09 JamC-CddCurK 3.8 20.6 
3 pWP11 JamC-CddJamK 7.3 20.5 
4 pWP50 JamC(E32T) 3.4 14.3 
5 pWP51 JamC(E32H) 4.6 14.3 
6 pWP15 LipPKS1* 7.2 192.8 
7 pWP17 NddCurL-LipPKS* 3.4 197.0 
8 pWP19 NddJamL-LipPKS* 2.6 196.6 
9 pSY122 DEBS6M6* 9.2 182.9 
10 pWP39 NddCurL-DEBSM6* 3.2 182.9 
11 pWP40 NddJamL-DEBSM6* 7.6 182.5 
  
Figure S1. Engineered proteins expressed and purified in this study, related to Figure 2. A. SDS PAGE gel 
depicting affinity chromatography purified proteins. B. Table giving yields and expected size of proteins shown 
in the above gel.  
  
   2  
  
  
  
Figure S2. JamA and JamC produced the expected product with LipPKS1* and DEBSM6*, related to Figure 2. 
A. Overview scheme of in vitro reactions between JamA/JamC and model PKSs. B. Terminal alkyne product was 
observed with both PKSs when JamA, JamC, and the PKS are present, but no detectable amounts are observed 
with the omission of JamC and only trace amounts observed with the inclusion Orf35 in place of JamC. C. 
Comparison of DEBSM6*/LipPKS1* products to a synthetic standard of alkyne product 1. All solutions in panel 
C were injected at 15 µl/run with the standard injected at 0.5 ng/mL The experiments in panel A and B were run 
using an Agilent 6510 Accurate Mass QTOF while experiments in panel C were run on an Agilent 6545 accurate 
Mass QTOF with a slightly modified gradient (see methods section).  
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 Figure S3. 1H NMR spectra of compound 1 in CDCl3, related to Figure 2 and Figure 3. 
   4  
 
Figure S4. 13C NMR spectra of compound 1 in CDCl3, related to Figure 2 and Figure 3. 
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Figure S5. Docking domain alignments, related to Figure 2 and Figure 3. A. Alignments between JamC and 
CddCurK and CddJamK. Fusion sites for full JamC and also the shortened JamC are shown on the top alignment. 
Bottom alignment depicts predicted secondary structure of JamC and two helices swapped for longer portions of 
the docking domains. B. Model of JamC with two C-terminal helices colored salmon and the truncated (short 
JamC) fusion site highlighted. C. Alignments between LipPKS1, DEBSM6, CurL, and JamL PKSs with the fusion 
site for the N-terminal docking domains pointed out before the D/EPIAI motif.   
  
  
Figure S6. Longer swap of CddCurK and CddJamK docking domains do not produce detectable product in vitro, 
related to Figure 2. Reactions were run at RT for 3h, followed by quenching with cold MeOH. EIC for alkyne 
product (1),155.0714 m/z is shown.   
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Figure S7. JamC mutagenesis, related to Figure 2 and Figure 3. A. Alignments of JamC compared to DEBSM2-
ACP, DEBSM4-ACP, DEBSM5-ACP, and LipPKS1-ACPL. B. Model of JamC residue E32, compared to 
DEBSM2-ACP residue E23 (PDB: 2JU1). The site directed mutagenesis was inspired by work performed on other 
modules from the DEBS pathway (Kapur et al., 2012; Klaus et al., 2016). The residue identified was from 
DEBSM2 and a mutation was made to mimic a residue on the native upstream ACP of DEBSM4. To identify the 
corresponding residue in JamC alignments of the ACP were performed with the DEBSM2 and DEBSM4 ACPs 
and JamC. The glutamate at residue 32 of JamC was identified as corresponding to DEBSM2 glutamate at ACP 
residue 23 through alignments and modelling. Mutating this JamC residue to mimic the native upstream ACP in 
the LipPKS1 and DEBSM6 required alignments of DEBSM2-ACP to the loading ACP of LipPKS1 and the 
DEBSM5-ACP, respectively. For the LipPKS1 system the residue was mutated to threonine (E32T), and for 
DEBSM6 to histidine (E32H).  
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Figure S8. 1H NMR spectra of compound 2 in CDCl3, related to Figure 2 and Figure 3.
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 Figure S9: 13C NMR spectra of compound 2 in CDCl3 related to Figure 2 and Figure 3. 
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Figure S10. DEBSM6* produced a majority of longer acyl products as compared to compounds 1, 2, related to 
Figure 3. Actual structures for compounds 1 and 2 are shown, while putative structures for other masses are 
displayed. The y-axis measures Area Under the Curve (AUC) from integrating EIC’s for each different 
compound’s mass (see materials and methods for formulas and exact masses).  Error bars represent SEM for n ≥ 
4 independent experiments.  
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Transparent methods  
  
General molecular biology methods:  
Q5 High-Fidelity DNA polymerase or Phusion High-Fidelity PCR Master Mix (NEB) were used for PCR 
reactions. Restriction enzymes were purchased from Thermo Scientific. Plasmid construction was performed 
using the aLICator LIC cloning and expression system (ThermoFisher Scientific), NEB Builder HiFi DNA 
assembly kit (NEB), or the rapid DNA ligation kit (ThemoFisher Scientific). Constructs for LipPKS1(pSY091) 
and DEBSM6 (pSY122) were a generous gift from the Keasling lab and the Joint Bioenergy Institute (Yuzawa et 
al., 2017). Oligonucleotides were ordered from Integrated DNA Technologies and all constructs were confirmed 
by sequencing through the UC Berkeley DNA sequencing facility. PCRs and digests were run on 0.8%-1% 
agarose gels and visualized using SYBR safe gel stain (ThermoFisher Scientific). Chemicals and media were 
obtained from Alfa Aesar, ThermoFisher Scientific, Sigma-Aldrich or other commercial vendors.   
  
Protein expression and purification.   
All proteins that were purified contained C- or N-terminal His6 tags. For protein expression all plasmids were 
transformed into E. coli BL21 (DE3) Star or BAP1 (for any ACP containing protein). For all proteins except 
JamA (see below for JamA procedure) the cells were grown at 37 °C in 1 L of LB medium with appropriate 
concentrations of antibiotics to an OD600 of 0.4–0.6. The cells were induced with 0.1-0.25 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 16 h at 16 °C. The cells were harvested by centrifugation (5,000 x g, 15 min, 4 
°C), resuspended in 30 ml of lysis buffer (50 mM HEPES, pH 8.0, 300 mM NaCl, 10 mM imidazole) and lysed 
by homogenization or sonication (Branson Sonifier 250, power 8, 15 min 30 % duty) on brined ice water. The 
resultant lysed cells were centrifuged (15,000 x g, 30 min, 4 °C) to remove cell debris. Ni-NTA agarose resin 
(Qiagen) was added to the supernatant (1-1.5 ml per 1 L of culture), and the solution was nutated at 4 °C for 1 h. 
The protein resin mixture was loaded onto a gravity flow column, and proteins were eluted with increasing 
concentrations of imidazole in 50 mM HEPES, pH 8.0, 300 mM NaCl. Purified proteins were concentrated using 
Amicon Ultra filters, and the buffer was exchanged to remove imidazole with 50 mM HEPES, pH 8.0, 100 mM 
NaCl. The final proteins were flash-frozen in liquid nitrogen and stored at −80 °C. Protein concentrations were 
determined by NanoDrop with extinction coefficients calculated using the ExPASy ProtParam tool. Proteins were 
assessed for correct size and purity by running on mini-PROTEAN precast gels (4-20%, Bio-Rad) at 170 V for 
27 min, followed by staining with Bio-Safe Coomassie stain (Bio-Rad). The approximate protein yields are 
displayed above.   
Altered protocol for JamA expression and purification. JamA was transformed into E. coli BL21 (DE3) star cells 
and grown in autoinduction media (Studier, 2014) for 2 h at 37 °C followed by 16 °C for 12 h. Purification 
followed the above steps, however 10 % glycerol was included in the buffers during Ni-NTA binding and 
subsequent purification and buffer exchange steps.  
  
In vitro enzyme assays:  
All assays were performed in 100 mM HEPES (pH 8.0) buffer containing 2 mM MgCl2, 20 mM sodium malonate, 
2.5 mM TCEP, 1 mM NADPH, 5 mM ATP, 5 mM fatty acid, 2 mM CoA. Malonyl-CoA was generated in vitro 
with the addition of 10 µM MatB. The following enzymes, when present, were at the following final 
concentrations: 50 µM ACP, 20 µM PKS, 15 µM JamA, 5 µM Orf35. Reactions were performed at RT for the 
time indicated (30 min - 3 h). Reactions were quenched with 2 x volume of cold MeOH, followed by centrifugation 
at 21.1 x g for 3 min. Analysis was performed with LC/HRMS (15 μl injection) with an Agilent Eclipse Plus C18 
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column (4.6 × 100 mm) and Agilent Technologies 6510 in negative mode. Eluting with a linear gradient of 2–
95% MeCN (v/v) over 13 min in H2O supplemented with 0.1% (v/v) formic acid at a flow rate 
of 0.5 ml/min.  In the experiments shown in Fig. S2C all parameters are the same as the previous sentence besides 
the reaction run on an Agilent 6545 Accurate Mass QTOF with a linear gradient of 2-98% MeCN (v/v) over 13 
min. 
  
In vivo production of 3-hydroxy-7-hexenoic acid and 3-hydroxy-7-hexynoic acid.   
BAP1 cells with plasmid pWP34 (pCDFDuet containing JamA and JamB) along with a pETDUET plasmid 
containing the ACP and PKS were grown in 100 ml of LB medium with 100 μg/ml carbenicillin and 100 μg/ml 
spectinomycin at 37 °C to an OD600 of 0.4–0.6. Subsequently, the cells were centrifuged and resuspended in 25 
mL F1 media (60 mM phosphate buffer, pH 7, 30 mM ammonium sulfate, with the following added fresh to a 
final concentration of 1.25 mM MgSO4, 0.5 % (w/v) glucose, 100 µM Fe(NH4)2(SO4)2) supplemented with 1.25 
mL trace metal solution, 10 mL 100 x vitamin solution, 100 μg/ml carbenicillin, 100 μg/ml spectinomycin, 0.5 
mM IPTG and 1 mM 5-hexenoic acid. After 72 h of growth at 16 °C, 1 mL of cell culture was added to a 2 mL 
Eppendorf tube followed by acidification to ~ pH 1 with formic acid (35 µL formic acid). The cell culture was 
extracted with EtOAc (500 µL x 3). The organic fractions were combined and concentrated using a nitrogen 
evaporator (Techne). The extract was redissolved in 60 µL MeOH, transferred to mass spec vials and analyzed 
by HPLC and LC/HRMS (3 μl injection) with an Agilent Eclipse Plus C18 column (4.6 × 100 mm). Eluting with 
a linear gradient of 2–98% MeCN (v/v) over 13 min in H2O supplemented with 0.1% (v/v) formic acid at a flow 
rate of 0.5 ml/min. LC/HRMS analysis was performed on an Agilent Technologies 6545 Accurate Mass QTOF 
LC/MS in negative mode. Product titers were quantified by calibration to synthetic standards. Integration of 
product ions from MS/MS fragmentation (Fragmentor set to 100 V and collision energy at 5 V) was performed 
using the following transitions: 3-hydroxy-7-octenoic acid 157.086 à 59.01 m/z, 3-hydroxy-7-octynoic acid 
155.071 à 59.01 m/z. Standard curves were generated for 3-hydroxy-7-octenoic acid (from 50 µg/mL à 0.5 
ng/mL, if titer was greater than 50 µg/mL the extract was diluted ten-fold to fit the calibration range) and 
3hydroxy-7-octynoic acid (20 µg/mL à 0.5 ng/mL). Data were analyzed and visualized using Agilent 
MassHunter Q-TOF quantification software and Microsoft Excel. Other compounds besides 1 and 2 with putative 
structures shown in Figure S10 were confirmed to have the same carboxylic acid MS2 fragment (59.01). The 
formulas and masses included in other compounds are: C8H15O3-–159.1027, C10H15O3-–183.1027, C10H17O3-–
185.1183,  
C10H19O3-–187.1340, C12H19O3-–211.1340, C12H21O3-–213.1496, C12H23O3-–215.1653. At least three 
independent replicates were performed, and error bars represent SEM.   
  
Engineered LipPKS1* and DEBSM6*  
 Previous engineering of the LipPKS1 and DEBSM6 modules swapped the native AT domain for a malonyl-CoA 
accepting derivative (in our work we used the AT domain derived from the indanomycin module 9 for LipPKS1* 
and the AT from epothilone module 4 for DEBSM6*) in addition to the thioesterase domain of DEBSM6 fused 
to the C-terminal end of LipPKS1*, all of these constructs were first reported by Yuzawa et al. (Yuzawa et al., 
2017) and obtained from the Keasling lab and the Joint Bioenergy Institute.   
DEBSM6* was used without further modification in our studies however, LipPKS1 was further modified 
through removing of the loading domains to create LipPKS1*. The truncation site was chosen based on alignments 
to other PKSs and the reported site of docking domain fusions (Fig. S5C). Residues 1-646 of LipPKS1 were 
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removed so that the truncated LipPKS1* begins with the EPIAIV motif. Alignments were performed using Clustal 
Omega with default settings on the MPI Bioinformatics Toolkit server (Zimmermann et al., 
2018).  
  
Docking domain alignments and fusions  
 Docking domains from the Curacin and Jamaicamide biosynthetic pathways identified by Whicher et al. (Whicher 
et al., 2013). Incorporation of these docking domains necessitated identifying proper fusion sites at the C-terminus 
of JamC and the N-terminus of the PKSs. To identify the proper sites, we used alignments of the ACPs and PKSs 
along with structural modeling (Fig. S5A). Two orientations of JamC-docking domain fusions were identified and 
tested. One with the full JamC ACP with the docking domain appended to the C-terminus and the second with 
the last 19 residues of JamC were swapped with either CurK or JamK to replace small helices on JamC with those 
of CurK or JamK in addition to the docking domain (Fig. S5-S6). These CddCurK/JamK constructs were tested with 
the corresponding NddCurL/JamL-LipPKS1* synthase (Fig. S2, S6). The fusion site for the LipPKS1* and DEBSM6* 
with docking domains were more readily identifiable through alignments thus only one orientation was tested 
with fusing the docking domain in front of the “D/EPIAI motif” (Fig. S5C).  
JamC was modelled using CurA ACPI (PDB: 2LIU) as the parent structure, with the Robetta online server 
(Song et al., 2013). All alignments were done using Clustal Omega with default settings on the MPI 
Bioinformatics Toolkit server (Zimmermann et al., 2018).  
  
Site directed mutagenesis identification  
The site directed mutagenesis was inspired by work performed on other modules from the DEBS pathway 
(Kapur et al., 2012; Klaus et al., 2016). The residue identified was from DEBSM2 and a mutation was made to 
mimic a residue on the native upstream ACP of DEBSM4. To identify the corresponding residue in JamC 
alignments of the ACP were performed with the DEBSM2 and DEBSM4 ACPs and JamC. The glutamate at 
residue 32 of JamC was identified as corresponding to DEBSM2 glutamate at ACP residue 23 through alignments 
and modelling (Fig. S7). Mutating this JamC residue to mimic the native upstream ACP in the LipPKS1 and 
DEBSM6 required alignments of DEBSM2-ACP to the loading ACP of LipPKS1 and the DEBSM5-ACP, 
respectively (Fig. S7A). For the LipPKS1 system the residue was mutated to threonine (E32T), and for DEBSM6 
to histidine (E32H).  
 Alignments were performed using Clustal Omega with default settings on the MPI Bioinformatics Toolkit 
server (Zimmermann et al., 2018). JamC was modelled using CurA ACPI (PDB: 2LIU) as the parent structure, 
with the Robetta online server (Song et al., 2013).   
  
General synthetic methods:  
All reagents were purchased from commercial suppliers and used without further purification. (R)-3-Acetyl-
4benzyl-2-oxazolidinone (S3) was synthesized according to Nickerson et al. (Nickerson et al., 2016) and the 
spectra matched reported literature values (Ager et al., 1996). Reaction progress was monitored by thin-layer 
chromatography on silica gel 60 plates (aluminum back, EMD Millipore) and visualized by UV light or stained 
with KMnO4. Compounds were purified by flash column chromatography using Fisher Scientific 230-400 mesh, 
60 Å, silica gel. NMR spectra were acquired with a Bruker Biospin spectrometer with a cryoprobe. All spectra 
were acquired at 298 K. 1H spectra were acquired at 400 MHz, 13C spectra were acquired at 100 MHz. Coupling 
constants (J) are provided in Hz and chemical shifts reported in ppm relative to residual non-deuterated NMR 
solvent. High resolution mass spectra were collected using an Agilent Technologies 6520 or 6545 Accurate-Mass 
Q-TOF LC-MS instrument.    
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Scheme S1: Synthetic route to alkene product 2 (A), and alkyne product 1 (B), related to 
Figure 2 and Figure 3. 
 
5-hexen-1-al (S2):  
5-hexen-1-ol (S1, 0.72 mL, 6.0 mmol) was added to DCM (60 mL) in a flame-dried round-bottom flask. The 
solution was cooled to 0 °C and stirred under N2. Dess-Martin periodinane (3.557 g, 8.386 mmol) was then added 
to the reaction mixture and stirred for 4.5 h while it warmed to RT. Upon consumption of starting material the 
reaction was diluted with DCM and washed with saturated sodium bicarbonate (2 x 100 mL). The aqueous layer 
was extracted with DCM and the organic layers were combined, dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified via flash chromatography (eluting with 9:1 to 7:3 hexanes:ethyl acetate) 
to provide S2 as a colorless liquid (0.25 g, 43%). The NMR spectra were consistent with previous reports 
(Hyugano et al., 2008).  
  
  
3-hydroxydec-9-enoic acid (2):  
(R)-3-Acetyl-4-benzyl-2-oxazolidinone (S3, 0.501 g, 2.29 mmol) was added to a flame-dried round-bottom flask, 
dissolved in DCM (22 mL), and cooled to 0 °C under N2. A 1.0 M solution dibutylboron triflate in DCM (2.51 
mL, 2.51 mmol) and DIPEA (0.48 mL, 2.7 mmol) were then added to the reaction flask and the mixture was 
stirred for 30 min at 0 °C followed by cooling to -78 °C. Aldehyde S2 dissolved in 2 mL DCM was then slowly 
added to the reaction mixture and stirred for 30 min at -78 °C before warming to RT and stirring an additional 1.5 
h. The reaction was monitored by TLC (7:3 hexanes:ethyl acetate) and upon consumption of starting material the 
reaction was cooled to 0 °C and quenched with 2.5 mL methanol, 1 mL 50 mM phosphate buffer (pH 7.4), and 2 
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mL of 10% H2O2 followed by additional stirring for 1 h. The reaction mixture was diluted with deionized water 
(20 mL) and extracted with DCM (3 x 20 mL). The organic layers were combined, dried over 
MgSO4, filtered, and concentrated in vacuo. A short silica column was run (eluting with 9:1 to 7:3 hexanes:ethyl 
acetate) and the relevant fractions were combined and concentrated. The concentrated material was dissolved in 
4:1 THF:H2O (2.2 mL), cooled to 0 °C and 30% H2O2 (2.7 mL) was added, followed by slow addition of 1.5 mL 
sat. LiOH (aq.). The reaction mixture was stirred at 0 °C for 2 h and then quenched with 3 mL sat. Na2SO3 and 
the mixture was extracted with DCM (2 x 10 mL). The organic layer was back-extracted with 10 mL water. The 
aqueous layers were combined, and the pH was lowered to 1 with 3 M HCl. The aqueous layer was then extracted 
with ethyl acetate (5 x 20 mL). The organic layers were combined, dried over MgSO4, filtered, and concentrated 
in vacuo to yield an opaque residue. The residue was purified by column chromatography (eluting with 9:1 to 3:2 
hexanes:ethyl acetate) to yield 2 as a colorless oil (0.071g, 18%). 1H NMR (400 MHz, CDCl3) d 5.84 (ddt, J = 
16.9 Hz, 10.2 Hz, 6.7 Hz, 1H), 5.03 (m, 2H), 4.09 (m, 1H), 2.61 (dd, J = 16.6 Hz, 3.2 Hz, 1H), 2.52 (dd, J = 16.6 
Hz, 8.9 Hz, 1H), 2.13 (app q, J = 7.1 Hz, 6.5 Hz, 2H) 1.67-1.42 (m, 4H). 13C NMR (100 MHz, CDCl3) d 177.8, 
138.4, 114.9, 67.9, 41.1, 35.8, 33.5, 24.7. HRMS (ES–) m/z: [M – H]—  calcd C8H13O3 157.0870, found 157.0875.  
  
5-hexyn-1-al (S6):  
5-hexyn-1-ol (S5, 0.67 mL, 6.1 mmol) was added to DCM (60 mL) in a flame-dried round-bottom flask. The 
solution was cooled to 0 °C and stirred under N2. Dess-Martin periodinane (3.630 g, 2.453 mmol) was then added 
to the reaction mixture and stirred for 4.5 h while it warmed to RT. Upon consumption of starting material the 
reaction was diluted with DCM and washed with saturated sodium bicarbonate (2 x 100 mL). The aqueous layer 
was extracted with DCM and the organic layers were combined, dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified via flash chromatography (eluting with 9:1 to 7:3 hexanes:ethyl acetate) 
to provide S6 as a colorless liquid (0.35 g, 60%). The NMR spectra were consistent with previous reports 
(Majmudar et al., 2016).   
  
3-hydroxydec-9-ynoic acid (1):  
(R)-3-Acetyl-4-benzyl-2-oxazolidinone (S3, 0.933 g, 4.26 mmol) was added to a flame-dried round-bottom flask, 
dissolved in DCM (42 mL), and cooled to 0 °C under N2. A 1.0 M solution dibutylboron triflate in DCM (4.68 
mL, 4.68 mmol) and DIPEA (0.89 mL, 5.1 mmol) were then added to the reaction flask and the mixture was 
stirred for 30 min at 0 °C followed by cooling to -78 °C. Aldehyde S6 dissolved in 2 mL DCM was then slowly 
added to the reaction mixture and stirred for 30 min at -78 °C before warming to RT and stirring an additional 1.5 
h. The reaction was monitored by TLC (7:3 hexanes:ethyl acetate) and upon consumption of starting material the 
reaction was cooled to 0 °C and quenched with 5 mL methanol, 2 mL 50 mM phosphate buffer (pH 7.4), and 4 
mL of 10% H2O2 followed by additional stirring for 1 h. The reaction mixture was diluted with deionized water 
(40 mL) and extracted with DCM (3 x 40 mL). The organic layers were combined, dried over MgSO4, filtered, 
and concentrated in vacuo. A short silica column was run (eluting with 9:1 to 7:3 hexanes:ethyl acetate) and the 
relevant fractions were combined and concentrated. The concentrated material was dissolved in 4:1 THF:H2O 
(4.0 mL), cooled to 0 °C and 30% H2O2 (4.9 mL) was added, followed by slow addition of 2.7 mL sat. LiOH 
(aq.). The reaction mixture was stirred at 0 °C for 2 h and then quenched with 5 mL sat. Na2SO3 and the mixture 
was extracted with DCM (2 x 20 mL). The organic layer was back-extracted with 20 mL water. The aqueous 
layers were combined, and the pH was lowered to 1 with 3 M HCl. The aqueous layer was then extracted with 
ethyl acetate (5 x 30 mL). The organic layers were combined, dried over MgSO4, filtered, and concentrated in 
vacuo to yield an opaque residue. The residue was purified by column chromatography (eluting with a gradient 
of 5% to 10% methanol in DCM) to yield 1 as a colorless oil (0.0081g, 1.1%). 1H NMR (400 MHz, CDCl3) d 
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4.11 (m, 1H), 2.63 (dd, J = 16.7 Hz, 3.3 Hz, 1H), 2.55 (dd, J = 16.7 Hz, 8.9 Hz, 1H) 2.29 (m, 2H), 2.01 (t, J = 2.6 
Hz, 1H) 1.811.60 (m, 4H). 13C NMR (100 MHz, CDCl3) d 177.4, 84.0, 68.8, 67.5, 41.1, 35.3, 
24.4, 18.2. HRMS (ES–) m/z: [M – H]— calcd C8H11O3 155.0714, found 155.0719.  
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Table S1: Plasmids used in this publication, related to Figure 2 and Figure 3. 
Name description vector Use 
pWP08 N-term-His WELQ-JamC pLATE52 JamC overexpression and purification 
pWP09 N-term-His WELQ-JamC(full)-CurK(short) pLATE52 JamC overexpression and purification 
pWP10 N-term-His WELQ-JamC(short)-CurK(long) pLATE52 JamC overexpression and purification 
pWP11 N-term-His WELQ-JamC(full)-JamK(short) pLATE52 JamC overexpression and purification 
pWP12 N-term-His WELQ-JamC(short)-JamK(long) pLATE52 JamC overexpression and purification 
pWP15 N-term-His WELQ-LipPKS-AT91 pLATE52 LipPKS1 overexpression and purification 
pWP17 N-term-His WELQ-CurL-LipPKS-AT91 pLATE52 LipPKS1 overexpression and purification 
pWP19 N-term-His WELQ-JamL-LipPKS-AT91 pLATE52 LipPKS1 overexpression and purification 
pWP20 pETDUET-JamC(WT) pETDUET Overexpression for in vivo production of terminal alkynes 
pWP23 pETDUET-JamC(wt)_LipPKS pETDUET Overexpression for in vivo production of terminal alkynes 
pWP27 pETDUET-JamC-CurKdd_CurLdd-LipPKS pETDUET Overexpression for in vivo production of terminal alkynes 
pWP29 pETDUET-JamC-JamKdd_JamLdd-LipPKS pETDUET Overexpression for in vivo production of terminal alkynes 
pWP30 pETDUET-NL-LipPKS pETDUET Overexpression for in vivo production of terminal alkynes 
pWP34 pCDFDuet-JamB(M5T)-JamA pCDFDUET Overexpression for in vivo production of terminal alkynes 
pWP39 pET_CurLdd-DEBSM6 pET DEBS6 overexpression and purification 
pWP40 pET_JamLdd-DEBSM6 pET DEBS6 overexpression and purification 
pWP41 pETDUET-JamC(WT)_DEBS6TE pETDUET Overexpression for in vivo production of terminal alkynes 
pWP48 pETDUET-DEBS6-TE pETDUET Overexpression for in vivo production of terminal alkynes 
pWP50 pLATE52-N-His-WELQ-JamC(E32T) pLATE52 JamC overexpression and purification 
pWP51 pLATE52-N-His-WELQ-JamC(E32H) pLATE52 JamC overexpression and purification 
pWP58 pETDUET-JamC(E32T)_LipPKS1 pETDUET Overexpression for in vivo production of terminal alkynes 
pWP59 pETDUET-JamC(E32T)-CurKdd_CurL-LipPKS1 pETDUET Overexpression for in vivo production of terminal alkynes 
pWP65 pETDUET-JamC(E32T)-JamKdd_JamL-LipPKS1 pETDUET Overexpression for in vivo production of terminal alkynes 
pWP73 pCDFDuet-JamB(M5T) pCDFDUET Overexpression for in vivo production of terminal alkynes 
PSY122 DEBS6-TE pET Overexpression and purification of DEBSM6 
PXZ23 JamA pET Overexpression and purification of JamA 
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Table S2: Primers used to generate plasmids, related to Figure 2 and Figure 3.   
Primer sequence (5´-->3´) Used for 
PWP24-His-WELQ-JamC-pLATE-fwd GGTTGGGAATTGCAAATGGAAAACTTAACCGTAGAAACC JamC cloning into pLATE52 for overexpression 
PWP25-JamC-wt-pLATE-Rev ggagatgggaagtcattaTGCACCAAAGTGCTCTG JamC docking domain cloning 
PWP26-JamC-fu-CurK-sh-Fwd GCTATGGCAGAGCACTTTGCAAATGATGTGATGCCGAT JamC docking domain cloning 
PWP27-CurK-sh-JamC-fu-Rev ATCGGCATCACATCATTTGCAAAGTGCTCTGCCATAGC JamC docking domain cloning 
PWP28-CurK-pLATE52-rev ggagatgggaagtCATTAGATTAACTTCTCCAAAGCTTCGAT JamC docking domain cloning into pLATE52 for overexpression 
PWP29-JamC-sh-CurK-long-Fwd tggggattggatctcaaaagaaataTCCTCTACCTTATTATTCGACTATCC JamC docking domain cloning 
PWP30-CurK-long-JamC-sh-Rev GGATAGTCGAATAATAAGGTAGAGGAtatttcttttgagatccaatcccca JamC docking domain cloning 
PWP31-JamC-fu-JamK-sh-Fwd GCTATGGCAGAGCACTTTCTGAAGGAAGTTATGGGCTG JamC docking domain cloning 
PWP32-JamK-sh-JamC-fu-Rev CAGCCCATAACTTCCTTCAGAAAGTGCTCTGCCATAGC JamC docking domain cloning into pLATE52 for overexpression 
PWP33-JamK-pLATE52-Rev ggagatgggaagtCATTACAACATCGACTTGATTTTCTCAA JamC docking domain cloning into pLATE52 for overexpression 
PWP34-JamC-sh-JamK-long-Fwd tggggattggatctcaaaagaaataCCTGGCACCGTCG JamC docking domain cloning 
PWP35-JamK-long-JamC-sh-Rev CGACGGTGCCAGGtatttcttttgagatccaatcccca JamC docking domain cloning 
PWP38-pLATE52-LipPKS-KS-fwd ggttgggaattgCAAgaaccaattgcgatcgtgg LipPKS1 cloning into pLATE52 for overexpression 
PWP39-TE-LipPKS-pLATE52-Rev ggagatgggaagtCATTAGCTGTTGCCGCCA LipPKS1 cloning into pLATE52 for overexpression 
PWP40-pLATE52-CurL-Fwd ggttgggaattgCAAATGAACCTTAAGCAAGAGCAG LipPKS1 docking domain cloning into pLATE52 for overexpression 
PWP41-LipPKS-KS-CurL-Rev ccacgatcgcaattggttcTTTTGATTGAGTCTCATACTTCTCTAACTT LipPKS1 docking domain cloning 
PWP41-CurL-LipPKS-KS-Fwd AAGTTAGAGAAGTATGAGACTCAATCAAAAgaaccaattgcgatcgtgg LipPKS1 docking domain cloning 
PWP42-pLATE52-JamL-Fwd ggttgggaattgCAAATGGAACCTACCACGAATAAGG LipPKS1 docking domain cloning into pLATE52 for overexpression 
PWP43-LipPKS-KS-JamL-Rev ccacgatcgcaattggttcGGATTTAGCCAACTCCATCATC LipPKS1 docking domain cloning 
PWP44-JamL-LipPKS-KS-Fwd GATGATGGAGTTGGCTAAATCCgaaccaattgcgatcgtgg LipPKS1 docking domain cloning 
PWP48-JamC-all-Fwd catCCATGGAAAACTTAACCGTAGAAA JamC cloning into pETDUET 
PWP49-JamC-Rev catAAGCTTCTAtgcaccaaagtgctct JamC cloning into pETDUET 
PWP50-JamC-CurKdd-Rev catAAGCTTCTAGATTAACTTCTCCAACGCTTCGATTTCTTG JamC cloning into pETDUET 
PWP51-JamC-JamKdd-Rev catAAGCTTCTACAACATCGACTTGATTTTCT JamC cloning into pETDUET 
PWP52-LipPKS-wt-Fwd tacCATATGGAACCAATTGCGATCG LipPKS1 cloning into pETDUET 
PWP53-CurLdd-LipPKS-Fwd tacCATATGAACCTTAAGCAAGAGCA LipPKS1 cloning into pETDUET 
PWP54-JamLdd-LipPKS-Fwd tacCATATGGAACCTACCACGAATA LipPKS1 cloning into pETDUET 
PWP55-LipPKS-all-REV catCTCGAGtcaGCTGTTGCCGCC LipPKS1 cloning into pETDUET 
PWP56-pETDUET-LipPKS-Fwd ttaagtataagaaggagatatacatATGGAACCAATTGCGATCGTGG LipPKS1 cloning into pETDUET 
PWP57-pETDUET-CurLdd-Fwd ttaagtataagaaggagatatacatATGAACCTTAAGCAAGAGCAGGAAAAAG CurL cloning into pETDUET 
PWP58-pETDUET-JamLdd-Fwd ttaagtataagaaggagatatacatATGGAACCTACCACGAATAAGGACC JamLcloning into pETDUET 
PWP59-LipPKS-pETDUET(end)-Rev cagcggtttctttaccagactcgagTCAGCTGTTGCCGCCACC LipPKS1 cloning into pETDUET 
PWP60-pETDUET(2nd MCS)-Fwd CTCGAGTCTGGTAAAGAAAC pETDUET MCS2 cloning 
PWP61-pETDUET(2nd MCS)-Rev ATGTATATCTCCTTCTTATACTTAACTAATATACTAAGATGGG pETDUET MCS2 cloning 
PWP74-pCDF-JamB-M5T-Fwd ctttaataaggagatataccATGTCAATGCCAACCGATGTGAGCAA JamB(M5T) mutation cloning into pCDFDuet 
PWP75-JamB-PCDF-rev gcaagcttgtcgacctgcagTTAAGCTAACTTCTTAGCTTCG JamB(M5T) mutation cloning into pCDFDuet 
PWP89-pET_Gibson-Rev ATGTATATCTCCTTCTTAAAGTTAAAC pET Gibson cloning for overexpression 
PWP90-pETGibson-Fwd GATCCGGCTGCTAACAAAGCC pET Gibson cloning for overexpression 
PWP91-pET-CurLdd-Fwd ttaactttaagaaggagatatacatATGAACCTTAAGCAAGAG pET CurL cloning for overexpression 
PWP92-CurLdd-DEBS6-Rev tcgcaatcggatcTTTTGATTGAGTCTCATACTTC DEBS6 docking domain cloning 
PWP93-CurLdd-DEBS6-Fwd gactcaatcaaaaGATCCGATTGCGATTGTGG DEBS6 docking domain cloning 
PWP94-DEBS6-pET-Rev ttcgggctttgttagcagccggatcTCAGTGGTGGTGGTGGTG DEBS6 into pET for overexpression cloning 
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PWP95-pET-JamLdd-Fwd ttaactttaagaaggagatatacatATGGAACCTACCACGAATAAG pET JamL cloning for overexpression 
PWP96-JamLdd-DEBS6-Rev TCGCAATCGGATCGGATTTAGCCAACTCCATC DEBS6 docking domain cloning 
PWP97-JamLdd-DEBS6-Fwd gttggctaaatccGATCCGATTGCGATTGTGG DEBS6 docking domain cloning 
PWP110_pETDUET-DEBS6_fwd ttaagtataagaaggagatatacatATGTCTGGTGATAACGGCATG DEBS6 cloning into pETDUET 
PWP111_DEBS6-pETDUET_rev cagcggtttctttaccagactcgagtcacgaattcccgccac DEBS6 cloning into pETDUET 
PWP144_JamC_E32T_fwd agatgaggttcagACCtggttgatttcttatc JamC mutagenesis cloning 
PWP145_JamC_E32T_rev gataagaaatcaaccaGGTctgaacctcatct JamC mutagenesis cloning 
PWP146_JamC_E32H_fwd AGATGAGGTTCAGCATTGGTTGATTTCTTATC JamC mutagenesis cloning 
PWP147_JamC_E32H_rev gataagaaatcaaccaATGctgaacctcatct JamC mutagenesis cloning 
PWP158_pETDUET_MCS1_fwd AAGCTTGCGGCCGCATAAT pETDUET MCS1 cloning 
PWP159_pETDUET_MCS1_rev GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGG pETDUET MCS1 cloning 
PWP160_pETDUET_JamC-Fwd ctttaagaaggagatataccATGGAAAACTTAACCGTAGAAAC pETDUET JamC cloning 
PWP161_pETDUET_JamC-Rev cattatgcggccgcaagcttCTATGCACCAAAGTGCTC pETDUET JamC cloning 
PWP162_pETDUET_CurKdd-Rev cattatgcggccgcaagcttCTAGATTAACTTCTCCAACG pETDUET JamC cloning 
PWP163_pETDUET_JamKdd-Rev cattatgcggccgcaagcttCTACAACATCGACTTGATTTTC pETDUET JamC cloning 
PWP166_QC_JamC_E32T_fwd cagtagatgaggttcagacctggttgatttcttatctatcacaa JamC mutagenesis cloning (quick change) 
PWP167_QC_JamC_E32T_rev ttgtgatagataagaaatcaaccaggtctgaacctcatctactg JamC mutagenesis cloning (quick change) 
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